After adjusting for age and cognition, which showed significant association with school enrollment, children who were not enrolled in school still showed a trend towards being more likely to have feeding difficulties, compared to those who were enrolled in school (adjusted odds ratio 2.41 (95% CI 0.92–6.00, p = 0.06).
Lower Glasgow Coma Scale showed a trend ( P = 0.06) as an independent predictor of ≥6‐mL growth but was an independent predictor of ICrH Expansion Scale change.
han SEVs and the use post-dilatation is associated with lower survival, while the use of pre-dilatation did not influence survival; (3) however, in regard to the multivariable analysis, survival was impaired by complex CAD, atrial fibrillation, ICU stay, and higher creatinine, while post-dilatation showed a trend towards increased mortality ( p = 0.06), independent of the transprosthetic gradient; and (4) this study included a large number of TAVI platforms (six platforms in total) and there was no heterogeneity in the survival outcomes, while the Portico and Navitor valves were associated with a higher likelihood of permanent pacemaker implantation.
At day 5, murine cells showed a trend toward an increased fusion index with 1 (Δ = 4.9%; p = .060) and 50 μM (Δ = 4.8%; p = .075), but not with 100 μM (Δ = 2.8%; p = .869).
FREM2|STOML3 rs4544127 showed a trend for association (p = 0.06).
The use of veteran transportation services showed a trend to decrease the rates of no-shows without reaching statistical significance (7% vs. 14.5%, p = 0.06).
Furthermore, a low PINI showed a trend toward increased risk of SSI (HR: 1.69, 95% CI: 0.99–2.89, p = 0.06) and was significantly associated with total infection (HR: 1.95, 95% CI: 1.16–3.26, p = 0.01) (Tables S6A and S6B ).
RRMS patients showed a trend for decreased pre-contrast ATVV, ATVV of veins with a diameter < .3 mm and VIF compared to SPMS (all p < .06).
Post hoc comparisons showed a trend for greater activation in the left compared to the right AMG for fearful task‐relevant faces, F (1, 19) = 3.98, p = 0.060, while there was no asymmetry for task‐irrelevant faces, F (1, 19) = 0.38, p = 0.54.
Subgroup analysis for the group of women with a history of emergency CD showed a trend toward decreased preoperative anxiety, despite the small sample size of this subgroup (n=17; P =.06).
The effect of the interaction between time and the treatment type for the scores in the SHAPS showed a trend which did not reach the level of statistical significance [F (4, 491.9) = 2.24, p = 0.06].
After adjusting by age, route of HIV infection, length of infection before cART and viral hepatitis coinfection, CCR2 rs1799864-AG genotype was significantly associated with INR status (OR [95% CI]: 1.80 [1.04–3.11]; p = 0.04), and CXCL12 rs1801157-TT genotype showed a trend (OR [95% CI]: 2.47 [0.96–6.35]; p = 0.06).
Notably, GGT showed a trend favoring SGLT2i with a borderline p-value ( P = 0.06 in the anti-diabetic drug subgroup), while FBG reduction lacked statistical significance.
In the mSDMT, group differences in accuracy and reaction time were non-significant, although pwMS showed a trend toward slower responses ( p = 0.06).
Face memory performance showed a trend of a negative correlation with autism severity, r = −.277, df = 45, p = .060 indicating better face memory performance in less severely affected children.
Low-dose tofacitinib significantly extended survival of ALS mice compared to untreated control ALS mice in the intervention (6.2 day increase; p = 0.02) and cycle (7.3 day increase, p = 0.004) regimens and showed a trend towards improvement in the prevention regimen (p = 0.06; Figure 1B ).
Participants with diabetes showed a trend for a 1-h phase delay ( p = 0.06).
In contrast, mice receiving BTS at 300 mg/kg showed a trend towards increased total distance traveled ( Figure 2C , p = 0.06) compared to HFD mice.
Several proinflammatory cytokines, such as Il1β, Il1α, Tnfα, Cd86, IL6, and Trem2, were significantly upregulated by SE, but no changes were induced by the CQ treatment except for Il6 and Trem2 , which showed a trend to increase ( p = .06) in CQ compared to VHC treatment (Table S1 ).
While bloodletting showed a trend toward greater improvement than drug therapy, the difference was nonsignificant (MD = −0.04; 95% CI: [−0.08, 0.00]; p = 0.06; Figure 14 ), with no heterogeneity ( I 2 = 0%, p = 0.94). 3.10.
Subgroup analyses showed a trend toward efficacy for the RCT (lumateperone) on response rate (RR = 1.32, p = 0.06), while post-hoc analyses demonstrated significant benefit (RR = 1.35, p < 0.001; Supplementary Figure 11 ).
PD showed a trend that was not significant ( p = 0.06) and no differences were observed in FAZa or FAZp. 3.3.
Patients who experienced PNP showed a trend toward a higher need for RF touch-up compared to the counterpart ( p = 0.06).
Although the resistance model showed a trend toward worse PFS (HR = 2.3, P = 0.06), significance was not reached.
Statistical analysis showed a trend toward increased somnolence in the BR group ( p = 0.06), though this did not reach statistical significance.